A preventable blood-induced synovitis that progresses to cartilage loss, deformity and end-stage joint failure
- A haemarthrosis is not a benign episode. Blood activates synovium, iron is toxic to chondrocytes and repeated bleeding causes a self-perpetuating cycle.
- The target joint is treated by prevention as well as surgery: factor prophylaxis, early bleed treatment, activity modification and physiotherapy are core care.
- Any elective operation requires a written perioperative haemostasis plan covering factor or non-factor therapy, inhibitor testing, monitoring, antifibrinolytics and rescue treatment.
- Do not aspirate a haemophilic joint routinely; aspiration is reserved for a specific diagnostic or pressure-relief indication with haemostasis cover and sterile technique.
- A total knee or hip arthroplasty can relieve pain and improve function, but infection, bleeding, stiffness, loosening and revision risks remain higher than in the general population.
- “The classic early sign is recurrent painful swelling and loss of extension in a target joint, often before plain radiographs show severe disease.
- “Haemophilic arthropathy is caused by repeated bleeding, not by a primary inflammatory arthritis, although synovitis can mimic rheumatoid disease.
- “The orthopaedic surgeon must speak to the haematologist before incision; factor replacement is a surgical intervention, not a prescription after the operation.
- “A new acute swollen joint in a patient with haemophilia may be a haemarthrosis, infection, fracture or inhibitor-related uncontrolled bleeding; examine and investigate rather than assume.
Define preoperative target, intraoperative dose, postoperative troughs, laboratory monitoring, duration and rescue therapy. The target depends on the operation, factor type, inhibitor and local protocol.
A patient who bleeds despite apparently adequate replacement may have an inhibitor, altered pharmacokinetics or non-adherence. Check inhibitor status and factor recovery before elective surgery.
Aspiration can introduce infection and cause additional bleeding. Use it only when the result changes management or pressure threatens skin/neurovascular structures, with haemostasis cover.
Fever, a hot joint, severe pain or a non-responsive effusion may be infection rather than another bleed. Obtain cultures and treat urgently in parallel with haemostasis.
Definition, Causes and Pathophysiology
Haemophilic arthropathy is chronic joint damage caused by recurrent haemarthrosis, classically in severe factor VIII or IX deficiency. Blood in the joint induces synovial hypertrophy, iron deposition, angiogenesis and inflammatory mediator release. The enlarged vascular synovium bleeds more easily, creating a cycle of haemarthrosis, cartilage injury, subchondral change, deformity and contracture.
Commonly affected joints
- knee;
- ankle and subtalar joint;
- elbow;
- hip and shoulder less often, but with potentially catastrophic pressure or avascular complications.
The severity depends on baseline factor level, prophylaxis, access to early treatment, inhibitor status, trauma, activity and the number of lifetime bleeds. A patient on modern prophylaxis may still present with advanced arthropathy after childhood exposure; a patient with few recorded bleeds may have under-recognised episodes.
Mechanisms of progression
- Iron from blood activates synovial macrophages and damages chondrocytes.
- Synovial hypertrophy and neovascularity increase the risk of further bleeding.
- Cartilage matrix is degraded and subchondral bone remodels.
- Recurrent pain causes guarding, muscle inhibition and flexion contracture.
- Deformity and altered loading accelerate joint destruction and disability.
Anatomy and Surgical Risk
The synovium is the target of early joint-preserving treatment, but the anatomy changes with chronic disease.
- Hypertrophic synovium can fill the suprapatellar pouch, gutters and posterior recesses, making arthroscopic visualisation difficult and increasing bleeding surfaces.
- Chronic knee flexion contracture shortens posterior structures and may require staged stretching rather than forceful correction.
- Repeated ankle bleeding damages the talocrural and subtalar cartilage; the syndesmosis and hindfoot alignment determine whether arthrodesis or arthroplasty is possible.
- The elbow has dense synovium around the radiocapitellar and ulnohumeral joints; the ulnar nerve is vulnerable during open surgery and deformity correction.
- The hip is deep and surrounded by major vessels and the femoral nerve; a tense haemarthrosis can threaten perfusion and requires urgent specialist management.
- Prior bleeds, injections and operations increase infection and scar risk. Protect the skin and plan vascular access and postoperative monitoring.
Every operation should preserve useful bone and motion where possible while anticipating difficult haemostasis and a higher risk of stiffness.
Clinical Presentation and Examination
Acute haemarthrosis
The patient reports rapid swelling, warmth, pressure and pain, often with loss of motion. In the knee, the joint may be held in slight flexion; in the ankle, the patient may avoid weight bearing. A young patient may describe a subtle "tingling" or tightness before visible swelling. A traumatic event is not required.
Examination
- look for swelling, flexed posture, bruising, skin tension and fever;
- feel for warmth, fluctuation and tenderness, comparing with the opposite side;
- assess passive and active motion gently and document the range at which pain begins;
- test neurovascular status and the skin over the joint;
- ask about recent factor treatment, response and inhibitor history.
A large tense effusion, neurovascular deficit, severe pain out of proportion or skin compromise requires urgent specialist review. A hot joint with fever or persistent pain may be septic arthritis, not a routine bleed.
Chronic arthropathy
Look. Assess varus or valgus, flexion deformity, quadriceps wasting, ankle equinus, gait and limb length. In the ankle, look for hindfoot varus/valgus and a plantigrade or equinus foot.
Feel. Palpate joint-line tenderness, synovial thickening, crepitus and warmth. A fluctuant mass may be a haemophilic pseudotumour rather than simple synovitis.
Move. Measure active and passive range with a goniometer. Record fixed flexion, extension loss, rotation and pain. In the knee, document straight-leg raise and extensor lag; in the elbow, record flexion, extension and forearm rotation; in the ankle, dorsiflexion with knee extended and flexed.
Function. Record walking distance, stairs, transfers, work and school, aids, analgesic use and bleed-related absence. Patient-reported function can deteriorate before radiographic collapse.
Differential diagnosis of a swollen joint
- acute haemarthrosis;
- septic arthritis;
- fracture or osteochondral injury;
- crystal arthritis;
- inflammatory arthritis;
- synovial tumour or haemophilic pseudotumour;
- inhibitor-related bleeding that does not respond to usual factor replacement.
Investigations
Blood tests and haemostasis
Before elective surgery obtain factor activity, inhibitor titre, full blood count, iron status when chronic bleeding is present, renal and liver function and the tests required by the haemophilia centre. Do not infer factor recovery from a historical dose; pharmacokinetics vary.
Radiographs
Request joint-specific views:
- knee: standing AP, lateral and skyline patella views when tolerated;
- ankle: weight-bearing AP, mortise and lateral views, with hindfoot alignment if deformity is present;
- elbow: AP and lateral views with obliques when osteophytes or loose bodies are suspected;
- hip: AP pelvis and cross-table lateral, with full femur if arthroplasty is planned.
Record joint space, erosions, subchondral cysts, osteophytes, deformity, epiphyseal overgrowth, osteopenia, loose bodies and alignment. The Pettersson score is useful for longitudinal assessment but should not replace a clinical and functional decision.
MRI and ultrasound
MRI detects synovial hypertrophy, hemosiderin, cartilage, osteochondral injury, soft-tissue mass and pseudotumour. Gradient-echo or susceptibility-sensitive sequences accentuate hemosiderin. Ultrasound can detect effusion, synovial hypertrophy and muscle or tendon pathology and can guide an indicated aspiration or injection under haemostasis cover.
Aspiration
Aspirate only when septic arthritis, crystal disease, a tense effusion or an alternative diagnosis must be distinguished and the result will change management. Use strict sterile technique, a small-gauge needle when appropriate, factor or bypassing-agent cover and a post-procedure compression/observation plan. Send cell count, differential, Gram stain where used, culture and crystal analysis.
Prevention and Non-Operative Management
The first-line strategy is to prevent bleeding and preserve movement:
- individualised factor VIII or IX prophylaxis, or non-factor therapy where indicated;
- rapid recognition and treatment of suspected bleeds according to the haemophilia centre plan;
- inhibitor screening when bleeding is unexpected or factor recovery is poor;
- physiotherapy for range, strength, proprioception and gait without high-impact loading;
- weight management, footwear, orthoses and activity modification;
- analgesia that avoids platelet inhibition when possible and is coordinated with haematology;
- dental and procedural planning to reduce avoidable bleeding and infection.
Repeated aspiration, corticosteroid injection or NSAID use should not be routine. Every injection is a bleeding and infection event and needs haemostasis cover and a clear indication.
When prophylaxis starts decides what it can achieve
The list above says individualised prophylaxis without saying when, and the timing is the whole argument. Two randomised trials from the same group answer it from opposite ends of life, and an orthopaedic surgeon should be able to state both.
- Started in infancy, it prevents structural damage - incompletely. The Joint Outcome Study randomised boys with severe haemophilia A to prophylaxis before age 2.5 or to episodic treatment. Followed to age 18 (PMID 32492157), 77 per cent of the delayed group had MRI osteochondral damage against 35 per cent of the early group - odds ratio 6.3 (95 per cent CI 1.3 to 29.9, p = 0.02) - with annualised bleeding of 10.6 against 3.5. Note the honest half of that result: a third of the children treated from a mean age of 1.3 years still had joint damage at 18. Prophylaxis is not a guarantee, which is why these patients stay under orthopaedic surveillance however well their haematology is managed.
- Started in adulthood on a damaged joint, it improves the patient but not the joint. SPINART (PMID 28836341) randomised adults with severe haemophilia A and established arthropathy to three years of prophylaxis or on-demand treatment: a 94 per cent reduction in bleeds, 35.7 per cent completely bleed-free, better joint-health scores, better function and half the chronic pain - yet MRI progression was no different (least-squares mean change +0.79 against +0.96). The authors' conclusion is the sentence for a viva: pre-existing arthropathy may be irreversible.
What this changes at the clinic door. Tertiary prophylaxis in an adult with an established target joint is worth offering for bleeding, pain and function - but consent for it honestly. It will not reverse the joint and it does not measurably slow its radiographic decline, so it postpones nothing about planning for eventual surgery. Conversely, a young patient whose prophylaxis is late, interrupted or non-adherent is accumulating damage that no later intensification recovers, and that is the argument to take back to the haemophilia centre.
Radiosynovectomy
Radiosynovectomy can reduce recurrent bleeding in a target joint after a haemophilia-centre assessment, appropriate imaging and factor cover. It is not a substitute for adequate prophylaxis or a treatment for advanced mechanical collapse. Protect the patient and staff according to the radionuclide protocol.
Chemical or open synovectomy
Synovectomy may be considered when recurrent bleeding persists despite optimal prophylaxis and the joint is not end-stage. Arthroscopic synovectomy is less invasive but may leave posterior or difficult recesses; open synovectomy can be more complete but increases wound, blood-loss and stiffness risk. The operation should be joint-specific and performed with an experienced haemostasis team.
Surgical Indications and Choice
Synovectomy is considered for recurrent target-joint bleeding with hypertrophic synovium despite optimised medical treatment, especially before irreversible cartilage loss. Treat infection and correct a mechanical lesion first.
Arthrolysis or corrective surgery may be used for painful fixed contracture, deformity, impingement or loose bodies when the joint is still salvageable. Motion must be protected with factor cover and early guided physiotherapy.
Arthrodesis is reserved for selected painful end-stage joints where a stable painless position is more useful than motion and arthroplasty is unsuitable. An ankle fusion may be appropriate in severe haemophilic ankle destruction; a knee fusion is a salvage option after failed infection or arthroplasty rather than a first-line procedure.
Arthroplasty is considered for end-stage pain and functional loss after non-operative care fails. The knee is most commonly replaced; hip, elbow and ankle arthroplasty are more selective. Discuss bleeding, infection, stiffness, loosening, instability, revision and the need for lifelong haemophilia care.
- Best fit
- Recurrent target-joint bleeding with synovitis and salvageable cartilage
- Main benefit
- Reduces synovial bleeding without open surgery
- Main risk
- Incomplete response, radiation/procedure risks and need for factor cover
- Best fit
- Persistent hypertrophic synovium despite prophylaxis
- Main benefit
- Reduces synovial volume and bleed frequency
- Main risk
- Bleeding, infection, stiffness and incomplete posterior clearance
- Best fit
- End-stage painful joint with functional disability
- Main benefit
- Pain relief and improved function
- Main risk
- Bleeding, infection, stiffness, loosening and revision
- Best fit
- Selected painful unreconstructable joint or failed arthroplasty
- Main benefit
- Stable painless lever
- Main risk
- Permanent stiffness, nonunion and altered gait
Perioperative Haemostasis and Surgical Planning
The haemophilia centre must write the factor plan before the operation. Exact targets depend on factor type, inhibitor, operation, pharmacokinetics and local protocol; the following is a framework from the WFH guideline rather than a dose prescription.
Major surgery framework
- severe haemophilia A or B commonly requires a preoperative factor activity target of approximately 80 to 100 IU/dL;
- postoperative targets are commonly maintained at approximately 60 to 80 IU/dL during days 1 to 3, 40 to 60 IU/dL during days 4 to 6 and 30 to 50 IU/dL during days 7 to 14, with individual adjustment and laboratory monitoring;
- factor levels should be checked at the centre's specified time after dosing and before subsequent doses when interpreting recovery;
- patients with inhibitors may require bypassing agents or a non-factor strategy under specialist supervision;
- tranexamic acid may reduce mucosal and orthopaedic bleeding in suitable patients, but renal, thrombotic and drug-specific contraindications must be reviewed;
- desmopressin is useful only in selected mild haemophilia A patients with a documented response and is not a replacement for a major-surgery plan.
The operation briefing must include
- diagnosis, inhibitor status and factor product;
- preoperative target, dose, timing, intraoperative monitoring and postoperative trough schedule;
- access for rapid infusion, blood products and rescue bypassing therapy;
- tourniquet and cell-salvage plan;
- antibiotic and thromboprophylaxis plan balancing bleeding and venous thrombosis;
- drain, wound and physiotherapy plan;
- emergency plan for uncontrolled bleeding or a failed factor response.
Do not use a tourniquet to compensate for absent haemostasis planning. A tourniquet can conceal bleeding, worsen tissue injury and delay recognition of an inadequate factor level.
Operative Technique: PIPADRAW
The steps below describe a planned knee synovectomy or arthroplasty; adapt to the joint and agree factor monitoring before incision.
Haemophilic joint surgery sequence
- Position the patient for the joint-specific approach, pad pressure points and keep the limb visible for swelling, perfusion and postoperative checks.
- Prepare the full limb and an access site for factor infusion. Record baseline neurovascular status and joint range.
- Confirm the factor product, dose timing, laboratory sampling and rescue medication with the haematology team before incision.
- Use fluoroscopy when hardware removal, osteotomy, severe deformity or arthroplasty alignment requires it.
- Have meticulous haemostatic tools, topical agents, cell salvage where appropriate, graft, implants and a plan for unexpected bone loss available.
- For arthroscopy, use low-pressure inflow and monitor swelling; for arthroplasty, plan the implant and bone cuts before factor dosing.
- Administer factor or bypassing therapy to the preoperative target immediately before surgery according to the written plan.
- Give antibiotics at the agreed time and obtain cultures before therapeutic antibiotics only when the patient is stable and infection is being assessed.
- Use careful positioning, warming and pressure protection; avoid unnecessary venepuncture and intramuscular injections.
- Use the safest joint-specific incision and preserve skin. Avoid multiple unnecessary portals or a large flap when a smaller approach is adequate.
- In a knee arthroplasty, use a medial parapatellar or extensile approach according to scars and extensor status.
- In an elbow, identify and protect the ulnar nerve; in an ankle, preserve skin bridges and the anterior neurovascular bundle.
- Evacuate clot and excise hypertrophic or infected synovium with controlled haemostasis. Send suspicious tissue for histology and culture.
- Avoid aggressive blind posterior dissection; use joint-specific portals or an extensile exposure with direct visual control.
- Preserve viable capsule, tendon and collateral structures that will support the joint or arthroplasty.
- For synovectomy, inspect all compartments and remove residual villous synovium without damaging cartilage or neurovascular structures.
- For arthroplasty, make bone cuts conservatively, manage osteopenia and correct deformity without stripping soft tissue.
- Prepare a plan for bone graft, stem extension, constrained bearing or fusion if the disease is more advanced than expected.
- Trial the arthroplasty or position the fusion with the joint-specific mechanical target.
- Check leg length, coronal alignment, flexion gap, patellar tracking, elbow stability or ankle plantigrade position as appropriate.
- Avoid forceful correction of a long-standing contracture that could cause fracture, neurovascular stretch or uncontrolled bleeding.
- Maintain direct visual control around the popliteal, posterior interosseous, ulnar, anterior ankle and neurovascular structures specific to the joint.
- Use controlled retractors and avoid unnecessary stripping. Maintain a vascularised closure over the implant.
- If bleeding exceeds the expected response, stop, pack, check factor level and activate the haemostasis plan rather than continuing blindly.
- Insert the selected implants with careful cement or press-fit technique and avoid unnecessary multiple passes through osteopenic bone.
- Secure the extensor mechanism, capsule, collateral or tendon repair. Use a drain only when it has a clear benefit and a planned factor/wound protocol.
- For fusion, prepare bleeding bone, apply stable compression and set the position that the patient can use.
- Obtain joint-specific radiographs when implants, osteotomy or alignment require confirmation.
- Check component position, fixation, fracture, joint line, patellar tracking, ankle plantigrade position or fusion alignment.
- Reassess pulses, motor function and skin before closure and after tourniquet release.
- Close without tension, apply compression and protect the wound. Continue factor or bypassing therapy according to the written schedule.
- Start gentle joint-specific physiotherapy when the surgeon and haematologist agree; avoid both prolonged immobilisation and uncontrolled loading.
- Monitor drain output, haemoglobin, factor levels, wound, fever, compartment symptoms and neurovascular status.
Postoperative Care and Complications
Early mobilisation reduces stiffness and thromboembolism but must match the operation and factor plan. Use physiotherapy to regain extension, maintain adjacent-joint motion and restore quadriceps or calf strength. Coordinate any manipulation under anaesthesia with haematology because it can cause major bleeding.
Complications
- postoperative haemorrhage or expanding haematoma;
- inhibitor or inadequate factor recovery;
- infection and wound breakdown;
- stiffness and flexion contracture;
- periprosthetic fracture, loosening or instability after arthroplasty;
- thrombosis despite a bleeding disorder;
- chronic pain, pseudotumour or recurrent haemarthrosis;
- nonunion after fusion.
A postoperative swollen joint needs a structured review: wound and temperature, factor level and inhibitor, haemoglobin, neurovascular status, imaging for fracture or implant problem, and aspiration only when the result changes management.
Guidelines, Registries & Global Practice
Global guidance. The World Federation of Hemophilia guideline emphasises early diagnosis, prophylaxis, rapid bleed treatment, inhibitor management, physiotherapy and coordinated surgery in a comprehensive haemophilia care model. Orthopaedic operations should be planned jointly with haematology; factor targets and duration are individualised by operation and pharmacokinetics [1].
Orthopaedic principles:
- prevent bleeding before treating its consequences;
- distinguish haemarthrosis from infection, fracture and inhibitor-related bleeding;
- use the least invasive effective synovial or joint procedure before end-stage arthroplasty;
- obtain culture and histology when infection is plausible;
- rehabilitate early but within the haemostasis and structural repair plan.
Registries. The World Bleeding Disorders Registry and national haemophilia registries track factor treatment, inhibitors, bleeds and joint outcomes, but surgical detail is not uniform. Centres should record target joints, synovectomy or arthroplasty, factor product and levels, inhibitor status, bleeding, infection, revision and function.
Global practice. Access to prophylaxis, non-factor therapy, radiosynovectomy, arthroplasty and physiotherapy varies. The treatment target is universal: prevent recurrent bleeding, preserve safe movement, and provide surgery only with a feasible haemostasis and rehabilitation plan.
MCQ Practice Points
Q: What drives haemophilic arthropathy? A: Repeated haemarthroses cause iron-mediated synovial hypertrophy, angiogenesis, cartilage injury, deformity and contracture. It is not simply an inflammatory arthritis.
Q: What is the target-joint approach? A: Optimise prophylaxis, treat bleeds early, use physiotherapy and consider radiosynovectomy or synovectomy when bleeding persists. Do not jump directly to arthroplasty while joint-preserving options remain.
Q: What is the perioperative priority? A: A written haematology-led factor or bypassing-agent plan with preoperative target, monitoring, postoperative troughs, inhibitor status and rescue therapy.
Q: When is aspiration justified? A: When septic arthritis, crystal disease, a tense effusion or another diagnosis must be distinguished and the result will change care. Perform it with sterile technique and haemostasis cover.
Q: What is a common surgical complication? A: Bleeding and haematoma, followed by infection, stiffness and implant failure. A normal preoperative factor dose does not guarantee adequate postoperative recovery.
Exam Viva Scenarios
Practise clinical reasoning and management decisions out loud
“A 19-year-old with severe haemophilia A presents with a painful swollen knee held in 20 degrees of flexion after a minor twist. He treated himself with one factor dose but remains swollen. He is afebrile and has no skin break. What do you do?”
“A 42-year-old with haemophilia A and no inhibitor has severe bilateral knee pain, 20-degree flexion contractures and radiographic joint-space loss. Prophylaxis and physiotherapy no longer provide function. What is your arthroplasty plan?”
“On day 2 after total knee arthroplasty, a patient has a rapidly enlarging tense knee, falling haemoglobin and prolonged pain despite the documented factor doses. What is your emergency assessment?”
Mechanism
- Recurrent haemarthrosis causes iron deposition, synovial hypertrophy, angiogenesis and cartilage injury
- Target joint: recurrent bleeds despite treatment; prevent progression early
- Knee, ankle and elbow are common; hip haemarthrosis can threaten perfusion
- Differentials: infection, fracture, crystal/inflammatory disease and pseudotumour
Assess
- Joint-specific examination, goniometry, gait, deformity, muscle wasting and function
- Serum factor activity/inhibitor, markers, radiographs and MRI/ultrasound as needed
- Aspiration only when it changes management, with sterile technique and haemostasis cover
- Document nerve, vascular, skin and baseline function before surgery
Treat
- Prophylaxis, rapid bleed treatment, physiotherapy, orthoses and activity modification
- Radiosynovectomy or synovectomy for persistent target-joint bleeding
- Arthroplasty for painful end-stage disease; fusion for selected salvage
- Written haematology plan for every procedure
Major surgery
- Preoperative factor target commonly 80 to 100 IU/dL for major surgery; verify local protocol
- Monitor postoperative troughs and inhibitor/response; use bypassing or non-factor therapy when indicated
- Plan cultures, antibiotics, blood conservation, thrombosis prevention and rehabilitation
- Bleeding, infection and stiffness require rapid multidisciplinary response
Evidence Base
The evidence base supports coordinated haemostasis, prevention and joint-specific surgery. Outcomes must be interpreted against the patient's factor regimen, inhibitor status and rehabilitation access. The two randomised trials below carry the central lesson of this page and they point the same way: prophylaxis started EARLY prevents structural joint damage; prophylaxis started LATE improves symptoms, function and bleeding but does NOT arrest structural progression.
Young Adult Outcomes of Childhood Prophylaxis for Severe Hemophilia A: Results of the Joint Outcome Continuation Study
- Long-term follow-up of the Joint Outcome Study randomised controlled trial, which had shown that starting prophylactic factor VIII before age 2.5 reduced joint damage at age 6
- 37 of 65 original participants were followed to age 18: 15 randomised to EARLY prophylaxis (mean age at start 1.3 years), 18 initially randomised to episodic treatment who began DELAYED prophylaxis at mean age 7.5 years, and 4 with high-titre inhibitors
- MRI OSTEOCHONDRAL DAMAGE AT EXIT: 77 per cent of the delayed group against 35 per cent of the early group - odds ratio 6.3 (95 per cent CI 1.3 to 29.9, p = 0.02)
- Annualised bleeding rate 10.6 plus or minus 6.6 with delayed against 3.5 plus or minus 2.1 with early prophylaxis (p less than 0.001), and still 6.2 against 3.3 when only the periods actually ON prophylaxis were compared
- THE AUTHORS' OWN CAVEAT, WHICH MATTERS AS MUCH AS THE HEADLINE: early prophylaxis was NOT SUFFICIENT TO FULLY PREVENT DAMAGE - 35 per cent of the early group still had osteochondral damage by 18
Effect of Late Prophylaxis in Hemophilia on Joint Status: A Randomized Trial (SPINART)
- Open-label randomised multinational trial: males aged 12 to 50 with severe haemophilia A, no inhibitors and no prophylaxis for over 12 months, randomised to recombinant FVIII prophylaxis or on-demand therapy for THREE YEARS
- A 94 PER CENT REDUCTION IN BLEEDING EVENTS despite severe pre-existing arthropathy; 35.7 per cent were completely bleed-free and 76.2 per cent had fewer than two bleeds per year
- Prophylaxis improved joint health (Colorado Adult Joint Assessment Scale, least-squares mean minus 0.31 against plus 0.63), quality of life, activity and satisfaction, halved chronic pain and roughly halved healthcare resource use
- BUT MRI SCORE CHANGE WAS NO DIFFERENT: least-squares mean plus 0.79 with prophylaxis against plus 0.96 on demand - structural arthropathy progressed in both arms
- The authors' conclusion is the sentence to remember: prophylaxis improves function but must start BEFORE joint bleeding begins to prevent arthropathy, and pre-existing joint damage may be IRREVERSIBLE
WFH Guidelines for the Management of Hemophilia, 3rd Edition
- The international reference standard: a 158-page practice guideline from the World Federation of Hemophilia, with an author panel including orthopaedic surgeons (Llinas, Goddard, Poonnoose) alongside haematologists
- Comprehensive care combines prophylaxis, rapid treatment of bleeds, inhibitor management and rehabilitation, delivered through a haemophilia treatment centre
- Perioperative factor targets are adapted to the specific operation and must be MONITORED rather than assumed from a dosing formula
- Orthopaedic surgery is to be coordinated with the haemophilia treatment centre from the decision to operate through to rehabilitation
The Mid-Term Clinical Outcomes of Total Knee Arthroplasty in the Management of End-Stage Hemophilic Arthropathy
- ELEVEN patients (15 knees) with STIFF knees from end-stage haemophilic arthropathy, mean age 40.8 plus or minus 11.8 years, mean follow-up 51.2 plus or minus 20.6 months
- Deliberately no adjunctive procedures - no posterior capsular release, hamstring release, synovectomy, VY quadricepsplasty or tibial tubercle osteotomy
- Flexion contracture fell from 17.6 to 1.7 degrees and maximum flexion rose from 55.6 to 109.2 degrees (p less than 0.001), with improvement continuing to 18 months postoperatively
- Knee Society Score rose from 22.7 to 87.8 (p less than 0.001)
- THE FIGURE THE ORIGINAL CARD OMITTED: coagulation factor consumption and blood transfusion accounted for 78 PER CENT OF THE TOTAL COST of treatment
Orthopedic Disorders of the Knee in Hemophilia: A Current Concept Review
- A narrative current-concept review of the knee in haemophilia, the commonest target joint
- The management sequence runs prevention and factor replacement, then physiotherapy, then synovial intervention, then arthroplasty
- Synovial interventions - radiosynovectomy and arthroscopic synovectomy - aim to interrupt the bleed-synovitis-bleed cycle BEFORE end-stage destruction
- Arthroplasty is reserved for the painful, function-limiting, end-stage joint
Aspects of Current Management: Orthopaedic Surgery in Haemophilia
- A review of orthopaedic surgery across the haemophilic skeleton, not confined to one joint
- Every orthopaedic procedure requires multidisciplinary factor management planned with the haemophilia centre
- Synovitis, fixed contracture and muscle wasting all influence the surgical result and must be assessed before the operation is chosen
- Structured rehabilitation is presented as protecting the functional gain rather than as an optional adjunct
References
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26 Suppl 6:1-158. PMID: 32744769. DOI: 10.1111/hae.14046.
- Rodriguez-Merchan EC, Valentino LA. Orthopedic disorders of the knee in hemophilia: a current concept review. World J Orthop. 2016;7:370-375. PMCID: PMC4911520. PMID: 27335812. DOI: 10.5312/wjo.v7.i6.370.
- Rodriguez-Merchan EC. Aspects of current management: orthopaedic surgery in haemophilia. Haemophilia. 2012;18 Suppl 4:84-89. PMID: 21535324. DOI: 10.1111/j.1365-2516.2011.02544.x.
- Adams JE, Reding MT. Hemophilic arthropathy of the elbow. Hand Clin. 2011;27:119-125. PMID: 21501786. DOI: 10.1016/j.hcl.2011.01.007.
- Rodriguez-Merchan EC, De la Corte-Rodriguez H. Complications of hemophilia in the elbow: current management. Expert Rev Hematol. 2020;13:989-1000. PMID: 32723183. DOI: 10.1080/17474086.2020.1803061.
- Kalkışım M, Okutan AE, Saraç Ü, et al. The mid-term clinical outcomes of total knee arthroplasty in the management of end-stage hemophilic arthropathy. Acta Orthop Traumatol Turc. 2022;56:145-150. PMCID: PMC9612652. PMID: 35416159. DOI: 10.5152/j.aott.2022.21131.
- De Kleijn P, Blamey G, Zourikian N, et al. Physiotherapy following elective orthopaedic procedures. Haemophilia. 2006;12 Suppl 3:108-112. PMID: 16684004. DOI: 10.1111/j.1365-2516.2006.01266.x.
- Luck JV Jr, Silva M, Rodriguez-Merchan EC, et al. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12:234-245. PMID: 15473675. DOI: 10.5435/00124635-200407000-00004.
- Nacca CR, Harris AP, Tuttle JR. Hemophilic arthropathy. Orthopedics. 2017;40:e940-e946. PMID: 28662249. DOI: 10.3928/01477447-20170619-05.
- Rodriguez-Merchan EC. Management of musculoskeletal complications of hemophilia. Semin Thromb Hemost. 2003;29:87-96. PMID: 12640570. DOI: 10.1055/s-2003-37942.
- Recht M, Konkle BA, Jackson S, et al. Recognizing the need for personalization of haemophilia patient-reported outcomes in the prophylaxis era. Haemophilia. 2016;22:825-832. PMID: 27581872. DOI: 10.1111/hae.13066.
- Warren BB, Thornhill D, Stein J, et al. Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Adv. 2020;4(11):2451-2459. PMID: 32492157. DOI: 10.1182/bloodadvances.2019001311.
- Manco-Johnson MJ, Lundin B, Funk S, et al. Effect of late prophylaxis in hemophilia on joint status: a randomized trial. J Thromb Haemost. 2017;15(11):2115-2124. PMID: 28836341. DOI: 10.1111/jth.13811.